RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma

Summary

This study is a prospective, open-label, multicenter, real-world clinical study to evaluate the efficacy and safety of tunlametinib in patients with NRAS-mutant advanced melanoma who have failed prior anti-PD-1/PD-L1 therapy.

Timeline

Start

2026-01-28

Primary completion

2028-09-30

Completion

2029-01-31

Drugs

Indications